CSF-1R Inhibitor

Elixiron Reports Positive Phase 2 Enrupatinib Data in Alzheimer’s Disease

CAMBRIDGE, Mass. and TAIPEI, June 10, 2026 Elixiron Immunotherapeutics announced positive interim results from its ongoing Phase 2 proof-of-concept...

By cGxPwire Editor
June 12, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

CSF-1R Inhibitor

Elixiron Reports Positive Phase 2 Enrupatinib Data in Alzheimer’s Disease